Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR1922T2 T-cell Therapy in R/R B-cell ALL and NHL
NCT06879262Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of CAR1922T2 T cells in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate at 3 years. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
CAR1922T2 T cells
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06879262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879262.